AngioDynamics (NASDAQ:ANGO) Updates FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of -0.380–0.340 for the period, compared to the consensus EPS estimate of -0.400. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $283.9 million. AngioDynamics also updated its FY25 guidance to ($0.38)-($0.34) EPS.

Wall Street Analyst Weigh In

ANGO has been the subject of several research analyst reports. Canaccord Genuity Group reduced their price objective on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of AngioDynamics in a report on Tuesday, December 10th.

AngioDynamics Trading Up 37.7 %

Shares of AngioDynamics stock opened at $12.94 on Thursday. The firm’s 50-day moving average price is $7.99 and its 200 day moving average price is $7.34. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $13.13. The firm has a market capitalization of $525.80 million, a PE ratio of -2.12 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The firm had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.05) earnings per share. On average, sell-side analysts predict that AngioDynamics will post -0.41 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.